---
schema_version: "secwatch.filing_event.v1"
accession: "0000927653-24-000104"
form_type: "8-K"
ticker: "MCK"
cik: "0000927653"
company_name: "MCKESSON CORP"
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:46:55.387986+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# McKesson signs deal to buy 70% of Core Ventures (FCS) for ~$2.49B cash

## Summary
- Purchase price approx. $2.49B in cash for ~70% controlling equity interest in Core Ventures (FCS's admin services org).
- Florida Cancer Specialists (250+ physicians, 280+ APPs, ~100 FL locations) to join McKesson's The US Oncology Network.
- Transaction subject to regulatory approvals and customary closing conditions; results reported in US Pharmaceutical segment.
- McKesson CEO Brian Tyler states deal expands community oncology platform, improves patient outcomes and reduces cost of care.
- FCS physicians retain minority interest in Core Ventures and remain independently owned.

## SEC filing metadata
- accession: 0000927653-24-000104
- form_type: 8-K
- ticker: MCK
- cik: 0000927653
- company_name: MCKESSON CORP
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/927653/000092765324000104/0000927653-24-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/927653/000092765324000104/mck-20240826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000927653-24-000104
- JSON: https://secwatch.observer/filing/0000927653-24-000104.json
- Plain text: https://secwatch.observer/filing/0000927653-24-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.